GenMark Diagnostics, Inc (GNMK) Director Acquires $42,200.00 in Stock
GenMark Diagnostics, Inc (NASDAQ:GNMK) Director Michael Kagnoff acquired 10,000 shares of the stock in a transaction dated Thursday, March 1st. The stock was bought at an average price of $4.22 per share, for a total transaction of $42,200.00. Following the purchase, the director now owns 74,413 shares of the company’s stock, valued at approximately $314,022.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of GenMark Diagnostics, Inc (GNMK) traded up $0.30 during mid-day trading on Monday, reaching $4.57. The company had a trading volume of 385,737 shares, compared to its average volume of 512,759. The company has a market capitalization of $250.41, a PE ratio of -3.75 and a beta of 0.99. GenMark Diagnostics, Inc has a 52-week low of $3.63 and a 52-week high of $13.67. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.04 and a current ratio of 3.44.
GenMark Diagnostics (NASDAQ:GNMK) last issued its earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26). The firm had revenue of $16.02 million during the quarter, compared to analysts’ expectations of $15.82 million. GenMark Diagnostics had a negative return on equity of 77.20% and a negative net margin of 90.74%. research analysts anticipate that GenMark Diagnostics, Inc will post -0.78 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its position in GenMark Diagnostics by 7.3% in the third quarter. JPMorgan Chase & Co. now owns 4,396,940 shares of the medical equipment provider’s stock worth $41,288,000 after purchasing an additional 299,173 shares during the period. Vanguard Group Inc. lifted its position in GenMark Diagnostics by 10.9% in the second quarter. Vanguard Group Inc. now owns 2,169,476 shares of the medical equipment provider’s stock worth $25,664,000 after purchasing an additional 212,795 shares during the period. State Street Corp lifted its position in GenMark Diagnostics by 9.4% in the second quarter. State Street Corp now owns 888,727 shares of the medical equipment provider’s stock worth $10,515,000 after purchasing an additional 76,010 shares during the period. Granite Investment Partners LLC lifted its holdings in shares of GenMark Diagnostics by 153.6% during the fourth quarter. Granite Investment Partners LLC now owns 215,760 shares of the medical equipment provider’s stock valued at $900,000 after acquiring an additional 130,677 shares during the period. Finally, Penn Capital Management Co. Inc. lifted its holdings in shares of GenMark Diagnostics by 56.4% during the fourth quarter. Penn Capital Management Co. Inc. now owns 543,715 shares of the medical equipment provider’s stock valued at $2,267,000 after acquiring an additional 196,150 shares during the period.
TRADEMARK VIOLATION WARNING: This piece was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/03/05/genmark-diagnostics-inc-gnmk-director-acquires-42200-00-in-stock.html.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.